Iambic Therapeutics Files Form S-1 for Nasdaq IPO Under IAM
Iambic Therapeutics filed a Form S-1 with the SEC to list on Nasdaq under IAM, backed by Nvidia and Coatue, with $207.9M in cash and clinical HER2 data.
biotech IPO
GLP-1 Startup Kailera Leads Biotech IPO Revival With $625M Deal
Kailera Therapeutics’ $625M GLP-1 IPO anchors a Q2 2026 healthcare listing wave, with Hemab Therapeutics, Avalyn Pharma, and peers all jumping 52-89% from their offer prices.